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Abstract
Background: Malaria, caused by the protozoan parasite Plasmodium, is one of the main causes of morbidity 
and mortality of the whole human population.Intensive, ongoing research aims to develop an effective 
vaccine against malaria; however, it has been unsuccessful for over a century. The circumsporozoite protein 
(CSP) plays crucial a role in the parasite life cycle. CSP is the most dominant surface antigen of the initial 
pre-erythrocytic stage. We designed vaccine constructs using four different CD4+ and CD8+ T cell epitopes 
derived from the CSP and used the lipid core peptide (LCP) as a self-adjuvanting delivery system.
Methods: All the constructs were synthesized using microwave-assisted solid phase peptide synthesis 
(SPPS). Immunological evaluation was carried out following subcutaneous administration of LCP-based 
vaccine candidates in a BALB/c mouse model. Interferon gamma (IFN-γ) production was used to measure 
the induction of epitope-specific cellular immune responses after vaccination.
Results: Self-adjuvanting LCP malaria vaccines composed of different epitopes were synthesized.To 
determine whether the vaccine candidates were able to induce cellular immunity, mice were immunized with 
LCP constructs or peptide epitopes adjuvanted with cholera toxin.Two of the tested constructs induced a 
high level of INF-γ in mice after subcutaneous immunization. 
Conclusions: We have demonstrated here for the first time that the LCP delivery system induced epitope-
specific cellular immune responses against an antigen derived from Plasmodium.
Keywords: Malaria, circumsporozoite protein (CSP), self-adjuvanting system, lipopeptide, peptide-based 
vaccine, cellular immune responses, CD4+ and/or CD8+ T-cell epitopes, INF-γ production
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Introduction
Malaria is considered as one of the most prevalent diseases 
in developing countries. It causes about one million deaths 
annually and is a major health problem worldwide [1,2]. Peo-
ple living in areas where rainfall and temperature favour the 
growth of Plasmodium parasites are at the highest risk [3]. 
Four Plasmodium species, P. falciparum, P. vivax, P. malariae, P. 
knowlesi and P. ovale infect humans. Severe cases of malaria 
are mostly caused by P. falciparum and P. vivax, which are 
prevalent in sub-Saharan Africa and Southeast Asia, respec-
tively [4-6]. The World Health Organization (WHO) launched 
the global malaria eradication programme in 1955 using 
chloroquine for the prevention and treatment of disease, and 
dichlorodiphenyltrichloroethane (DDT) for mosquito control 
[7]. The programme was abandoned in 1972 because of the 
emergence of Plasmodium parasites resistant to chloroquine 
and Anopheles mosquitoes resistant to DDT [8].
There are several drugs for the treatment of malaria nowa-
days; however, Plasmodium parasites are becoming resistant 
to majority of these medicines. In addition, the most effective 
treatments are often too expensive for many people in devel-
oping countries [9]. Despite intensive research is ongoing to 
develop an effective vaccine against malaria there is still no 
vaccine available on the market [10,11]. A complex life cycle 
and subsequent antigenic variations of the parasite are one of 
the major reasons for such a poor outcome [12].
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There are three major approaches for the development of vac-
cines against malaria and they are related to the parasite life 
cycle stage. Vaccine candidates are developed to target the 
pre-erythrocytic stage(sporozoite), erythrocytic-stage(blood), 
or to block transmission of the parasite. Pre-erythrocytic stage 
vaccines aim to protect against initial infections of malaria by 
targeting the sporozoites in the liver. Blood-stage vaccines 
aim to reduce the morbidity and mortality of the disease 
and target parasites present in red blood cells. Transmission-
blocking vaccines aim to block malaria transmission from 
mosquitoes to humans by preventing the malaria parasite 
from developing in the mosquito.
The circumsporozoite protein (CSP) is a major surface pro-
tein of the sporozoite (pre-erythrocytic) stage of malaria para-
site and is the antigenic target of numerous vaccines against 
malaria, including RTS, S. RTS, S is a recombinant protein-
based vaccine containing the CSP-derived sequences; the 
NANP-repeating region; and the thrombospondin-like type I 
repeat (TSR) domain, which are attached to the N-terminus of 
a hepatitis B surface antigen [13]. At the end of an 18 month 
phase III clinical trial, GlaxoSmithKline (GSK) reported in Oc-
tober 2013 that this vaccine reduced the amount of malaria 
cases among infants by 25% and among young children by 
50% [14]. RTS, S is currently the most advanced vaccine against 
malaria and targets the pre-erythrocytic stage.
Peptide-based vaccines usually incorporate the minimal 
peptide epitope required to induce the preferred immune 
response. These vaccines were effective at stimulating both 
humoral and cellular immunity. Importantly, peptide-based 
vaccines can be designed to stimulate only the desired immune 
response and can even trigger protective immune responses 
more efficiently than whole protein-based approaches [15,16]. 
In addition, peptide-based vaccines can be produced easily 
in large-scale with high purity, freeze-dried, stored in solid 
form and customized for an appropriate immune response 
[17]. However, peptides by themselves are not immunogenic 
and to overcome this problem an adjuvant or appropriate 
delivery system is necessary [18,19].
Herein a self-adjuvanting lipopeptide vaccine delivery 
system also known as the lipid core peptide (LCP) was used 
to develop a malaria vaccine [20]. The LCP system consists 
of three major components: (a) a non-microbial lipid moiety 
(composed of two copies of synthetic lipoamino acid (e.g., 
2-amino-d,l-hexadecanoic acid)), (b) a branching moiety, and 
(c) peptide epitopes [21]. The LCP system has been effective 
in delivering peptide-based vaccines against Chlamydia tra-
chomatis [22], group A streptococcus [23], human hookworm 
infection [24] and Schistosoma [25]. We have designed a pep-
tide vaccine based on the epitopes [26] derived from the CSP 
to induce immune responses that prevent malaria parasites 
entering into the bloodstream from the liver (Table 1). The 
vaccine constructs are comprised of the LCP delivery system 
and T-cell epitopes derived from the C-terminal fragment of 
the TSR domain. A CD8+ T cell immunodominant epitope on 
LCP Epitope 1 Epitope 2












Table 1. Lipid core peptide (LCP) constructs and sequence of 
incorporated epitopes. Overlapping region between epitopes 
P1 and P2 as well as P3 and P4 are marked in bold.
the sporozoite coat protein of P. yoelii (SYVPSAEQI) is nested 
within a dominant CD4+ T cell epitope (SYVPSAEQILEFVKQI) 
while CD8+ T cell epitopes (IYNRNIVNRL) is nested within a 
dominant CD4+ T cell (KIYNRNIVNRLLGD) [27]. Cellular im-
mune responses induced against these epitopes were able to 
confer at least partial protection against sporozoite challenge 
[28,29]. The immunogenicity of LCPs was evaluated based on 
the induction of epitope-specific cellular immune responses 
measured through the production of interferon gamma (INF-γ). 
Materials and methods
tert-Butoxycarbonyl (Boc) amino acids and p-methylbenzhy-
drylamine (pMBHA) resin were bought from Novabiochem 
(Switzerland). Trifluoroacetic acid (TFA), dichloromethane 
(DCM), N,N’-dimethylformamide (DMF), N,N’-diisopropy-
lethylamine (DIPEA) and methanol were purchased from 
Merck (Hohenbrunn, Germany). 1-[Bis(dimethylamino)
methylene]-1H-1,2,3-triazolo[4,5-b] pyridinium 3-oxid 
hexafluorophosphate(HATU) was obtained from Mimotopes 
(Clayton, VIC, Australia). HPLC grade acetonitrile was bought 
from Labscan (Bangkok, Thailand). All the other reagents were 
purchased at the highest available purity from Sigma-Aldrich 
(Castle Hill, NSW, Australia). Electrospray Ionization-Mass 
Spectrometry (ESI-MS) was performed on a Perkin-Elmer-
Sciex API3000 instrument with Analyst 1.4 software (Applied 
Biosystems/MDS Sciex, Toronto, Canada). Analytical Reverse 
Phase - High Performance Liquid Chromatography (RP-HPLC) 
was performed using an Agilent instrument with a 1 mL/min 
flow rate and detection at 214 nm. Separation was achieved 
using a 0-100% linear gradient of solvent B over 40 min with 
0.1% TFA/H2O as solvent A and 90% MeCN/0.1% TFA/H2O as 
solvent B on either a Vydac analytical C4 column (214TP54; 5 
mm, 4.6 mmx250 mm). Preparative RP-HPLC was performed on 
Shimadzu (Kyoto, Japan) instrument in linear gradient mode 




using a 10-20 mL/min flow rate, with detection at 230 nm. Sepa-
rations were performed with solvent A and solvent B on a Vydac 
preparative C4 column (214TP1022; 10 mm, 22 mmx250 mm). 
Synthesis of lipopeptides
LCPs were synthesized using microwave-assisted Boc chemistry 
by solid-phase peptide synthesis (SPPS) [30] at 20 W and 70°C 
similar to previous reports [20,31]. Briefly, the peptides were 
synthesized using pMBHAresin. The amino acid was activated 
by combining it with HATU and DIPEA for two minutes before 
it was added to the resin with the exception of 2-amino-d,l-
hexadecanoic acid which was activated five minutes prior to 
the coupling reaction. The resin was acetylated after the first 
amino acid was coupled. Coupling cycles consisted of 2×10 
min cycles for each amino acid. The Boc-protecting group was 
removed by treatment with TFA at room temperature for 2×1 
min. Resin was flow washed with DMF between couplings and 
deprotections. Once all the amino acids were attached, the 
resin was washed with DMF, DCM and methanol. After the 
synthesis was completed, the crude compound was cleaved 
from the resin using anhydrous HF. The product was then 
purified with preparative HPLC. C4 or C18 columns were used 
to analyse the samples in an analytical HPLC with a 0-100% 
gradient of Solvent B over forty minutes.
LCP 1
HPLC analysis (C4 column): tR=31.81 min, purity >95%. Yield: 
11%. ESI-MS: [M+2H]2+m/z 1571.7 (calc 1571.8), [M+3H]3+m/z 
1048.3 (calc 1048.2); MW 3141.79 g/mol.
LCP 2
HPLC analysis (C4 column): tR=30.54 min, purity >95%. Yield: 
12%. ESI-MS: [M+2H]2+m/z 1777.9 (calc 1778.6), [M+3H]3+m/z 
1186.2 (calc 1186.1); MW 3555.26 g/mol.
LCP 3 
HPLC analysis (C4 column): tR=30.80 min, purity >95%. Yield: 
10%. ESI-MS: [M+2H]2+m/z 2207.9 (calc2207.6), [M+3H]3+m/z 
1471.9 (calc 1472.1); MW 4413.29 g/mol.
Epitope P1
HPLC analysis (C18 column): tR=30.80 min, purity >95%. Yield: 
10%. ESI-MS: [M+2H]2+m/z 1034.9 (calc 1035.1), [M+3H]3+m/z 
518 (calc 518); MW 1034.12 g/mol.
Epitope P2
HPLC analysis (C18 column): tR=30.80 min, purity >95%. Yield: 
10%. ESI-MS: [M+2H]2+m/z 947.3 (calc 947.1), [M+3H]3+m/z 
632.6 (calc 631.7); MW 1892.16 g/mol.
Epitope P3
HPLC analysis (C18 column): tR=30.80 min, purity >95%. Yield: 
10%. ESI-MS: [M+2H]2+m/z 658.7 (calc 658.8), [M+3H]3+m/z 
439.4 (calc 439.5); MW 1315.52 g/mol.
Epitope P4
HPLC analysis (C18 column): tR=30.80 min, purity >95%. Yield: 
10%. ESI-MS: [M+2H]2+m/z 865.4 (calc 865.5), [M+3H]3+m/z 
577.7 (calc 577.3); MW 1728.99 g/mol.
Immunizations 
All the mice were immunized subcutaneously with 30 μg LCPs 
in 50 μL of phosphate buffered saline (PBS), 30 μg of peptides 
formulated with powerful classical adjuvant (P1+P3+cholera 
toxin (CT); P1+P4+CT; and P2+P3+CT) and PBS (negative 
control) followed by similar booster doses on days 21 and 42 
post primary immunization. Specific pathogen-free female 
BALB/c mice (Animal Resources Centre, Perth, Australia, n=5 
mice/group) were used at 5-6 weeks of age. The QIMR Ani-
mal Ethics Committee approved all animal studies and were 
conducted in accordance with the Australian Code of Practice 
for the Care and Use of Animals for Scientific Purposes (2004).
ELISPOT assay
Microplates (96-well) were initially pre-wet with 15 µL of 35% 
ethanol and then washed with PBS. These plates were coated 
with 75 µL of anti-mouse IFN-γ capture antibodies, sealed and 
stored overnight at room temperature, then, the plates were 
flicked to remove any unattached anti-mouse IFN-γ antibod-
ies. Splenocytes were harvested from the mice and a single 
cell suspension was prepared as reported previously [32]. Full 
media along with 10% fetal calf serum (FCS) and 100 µL of the 
purified cell suspension was added in each well (5X105 cells/
ml). Each peptide pool or individual peptides were added to 
triplicate wells, and cultures were incubated for 48 h at 37°C. 
The cell cultures were decanted and the wells were washed 
six times with PBS/Tween 20 using a plate washer. The plates 
were incubated for 60 min at 37°C in the presence of 75 µL 
biotinylated anti-mouse IFN-γ antibody in PBS, 0.5% of BSA 
and streptavidin. After the incubation time, the plates were 
thoroughly washed and 50 µL/well of 3-amino-9-ethylcarbazole 
(AEC) substrate was added. When dark spots emerged, the 
plates were washed under tap water to end the reaction. IFN-γ 
spot forming cells (SFCs) were counted using an ImmunoS-
potElispot counter and the number of spots in the wells was 
used to calculate the number of SFCs per million spleen cells. 
Statistical analysis
Statistical significance (p<0.05) was determined using a one-
way ANOVA with Bonferroni’s post-hoc test (GraphPad Prism, 
San Diego, CA).
Results and discussion
Malaria remains a major cause of mortality reaching a million 
deaths per year. Insecticide resistance of mosquito and drug 
resistance of the parasite are one of the significant reasons 
explaining the current increase in mortality rate [33]. Therefore, 
there is strong need for effective vaccine against malaria.
Sporozoite stage of malaria is characterized by presence 




of the parasites in the liver cells. Consequently, the vaccine 
developed against this stage should induce cellular immunity. 
Peptide-based vaccine candidates were designed to carry 
CD8+and CD4+ Tcell epitopes from CSP [26,29,34,35] to induce 
a cellular response against the sporozoite (pre-erythrocytic) 
stage of malaria. These epitopes were synthesized by micro-
wave assisted solid phase peptides synthesis (MW-SPPS) to 
produce: CD8+ T-cell epitope P1 (SYVPSAEQI), CD8+/CD4+ T-cell 
epitope P2 (SYVPSAEQILEFVKQI), CD8+ T-cell epitope P3 (IYN-
RNIVNRL) and CD8+/CD4+ T-cell epitope P4 (KIYNRNIVNRLLGD).
The peptide epitopes were also incorporated into the LCP 
system using MW-SPPS. Two different epitopes were attached 
to each LCP using lysine as a branching moiety (Table 1).
To determine whether the vaccine candidates stimulated 
cellular immune responses, BALB/c mice were immunized 
subcutaneously with LCP1-3, peptides formulated with power-
ful classical adjuvant (P1+P3+cholera toxin (CT); P1+P4+CT; 
and P2+P3+CT) and PBS (negative control) followed by the 
same doses on days 21 and 42 post primary immunization.
In cellular immunity, activation of CD4+ and CD8+ T cells, 
are crucial to protect against the liver stage of malaria [36]. 
Previous research has indicated that inhibition of malaria 
parasite development in the liver was predominantly related to 
IFN-γ production and CSP-specific CD8+ and CD4+ T cells were 
mainly responsible for its secretion [37]. Herein, following the 
immunizations, IFN-γ producing cells from the spleens were 
analysed by ELISPOT. The spleen samples were restimulated-
with a mixture of the epitopes used for immunization (Figure 1). 
To further examine which LCP and epitope combination 
induced the strongest cellular response, epitope-specific 
production of IFN-γ was also measured, by restimulating 
all the groups with individual peptides (in contrast to pre-
vious restimulation with whole peptide pool). Thus, LCP 1 
and the control groups were restimulated with a mixture 
of P1 and P3 peptides (Figure 2a); LCP 2 with a mixture of 
Figure 1. Production of IFN-γ in mice spleen after 
immunization with LCPs. Mice were vaccinated 
subcutaneously three times (on days 0, 21, and 42) with LCPs 
or peptide mixed with CT adjuvant. The IFN- γ level was 
measured after re-stimulation with (a) P1+P3; (b) P1+P4; (c) 
P2+P3 pooled peptides.
Figure 2. Production of IFN-γ in mice spleen upon immunization with LCPs. Mice were vaccinated subcutaneously three times (on 
days 0, 21, and 42) with LCPs or peptide mixed with CT adjuvant. The IFN-γ level was measured after re-stimulation with (a) P1 or 
P3; (b) P1 or P4; (c) P2 or P3 individual peptides.
P1 and P4 peptides (Figure 2b); and LCP 3 with a mixture of 
P2 and P3 peptides (Figure 2c). Once mice were immunized 
with peptide epitopes mixed with strong adjuvant (CT) all 
of them showed significant IFN-γ production. All LCPs also 
stimulated high levels ofIFN-γ production; of them LCP 2 
showed a significant increase in this cytokine secretion. Al-
though the CT adjuvant showed a high (expected) efficacy 
in stimulating a cellular response, it is not feasible to use 
this adjuvant in humans due to its toxicity [38]. To further 
examine which LCP and epitope combination induced the 
strongest cellular response, epitope-specific production of 
IFN-γ was also measured, by re-stimulating all the groups with 




individual peptides. Interestingly, upon this re-stimulation, a 
high level of IFN-γ production was detected in mice immu-
nized with CT and epitopes P3 or P4 (Figure 2). P1 showed 
lower potency to stimulate cellular responses but still signifi-
cantly higher than mice treated with PBS (Figures 2a and 2b). 
A similar tendency was observed in mice immunized with LCP 
1-3; significant responses were detected only for epitopes 
P3 and P4. Epitope P2, either incorporated in LCP construct 
or adjuvant formulations, did not induce any significant 
epitope-specific IFN-γ production. Therefore, among the 
epitopes tested, P4 could be lead target for future vaccine 
development as P3 epitope sequence is incorporated inside 
the P4. P4 epitope also comprises of both CD8+ and CD4+ T 
cell epitopes and therefore should be able to induce long 
lasting immune responses [39].
We have successfully demonstrated that the LCP delivery 
system usually used for production of antibodies can also 
induce strong IFN-γ production as a correlate of T cell activity. 
The cytokine production stimulated by the LCP constructs was 
not significantly lower than induced by classical adjuvant. The 
strength of response was clearly dependent on the choice of 
CD8+ T cell epitope. Two of the epitopes (P3 and P4) showed 
the ability of high IFN-γ production upon immunization with 
the help of adjuvant as well as when incorporated into LCP. As 
P4 epitope overlaps P3 sequence, therefore in future studies, 
P4 is the most promising candidate for developing an anti-
malaria vaccine. The ability to induce a cell-mediated immune 
response after vaccination with a self-adjuvanting LCP system 
supports the ability of the system to be used as a platform for 
development of vaccines targeting intracellular pathogens.
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